Last reviewed · How we verify
Tapinarof Cream 1%
Tapinarof is a topical aryl hydrocarbon receptor agonist that modulates the immune response and reduces inflammation.
Tapinarof is a topical aryl hydrocarbon receptor agonist that modulates the immune response and reduces inflammation. Used for Moderate to severe plaque psoriasis.
At a glance
| Generic name | Tapinarof Cream 1% |
|---|---|
| Sponsor | Teva Pharmaceuticals USA |
| Drug class | Topical aryl hydrocarbon receptor agonist |
| Target | Aryl hydrocarbon receptor |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 3 |
Mechanism of action
Tapinarof works by activating the aryl hydrocarbon receptor, which leads to the suppression of inflammatory cytokines and the induction of anti-inflammatory cytokines. This results in reduced inflammation and improved symptoms in patients with psoriasis.
Approved indications
- Moderate to severe plaque psoriasis
Common side effects
- Application site reactions
- Headache
- Pruritus
Key clinical trials
- A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis (PHASE3)
- Study to Evaluate the Safety and Efficacy of Tapinarof in Adults With Palmoplantar Keratoderma (PHASE2)
- Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects (PHASE3)
- Comparison of Post-Inflammatory Pigment Alteration After Psoriasis Treatment (PIPA - Dermavant) (PHASE2, PHASE3)
- Study Comparing Tapinarof Cream 1% To VTAMA ® (Tapinarof Cream 1%) In the Treatment of Plaque Psoriasis (PHASE3)
- Maximal Use Study of Tapinarof Cream, 1% in Pediatric Subjects With Extensive Atopic Dermatitis (PHASE2)
- Tapinarof for the Treatment of Atopic Dermatitis in Children and Adults (PHASE3)
- Tapinarof for the Treatment of Atopic Dermatitis in Children and Adults (DMVT-505-3102) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tapinarof Cream 1% CI brief — competitive landscape report
- Tapinarof Cream 1% updates RSS · CI watch RSS
- Teva Pharmaceuticals USA portfolio CI